Arrowhead Pharmaceuticals (A2RR34) Stock Overview

Develops medicines for the treatment of intractable diseases in the United States. More details

A2RR34 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 21.4% below our estimate of its fair value

Revenue is forecast to grow 29.74% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the BR market

Currently unprofitable and not forecast to become profitable over the next 3 years

A2RR34 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW474,966 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

474,966 investors already sharing narratives

View all narratives

Arrowhead Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Arrowhead Pharmaceuticals
Historical stock prices
Current Share Price	US$55.72
52 Week High	US$59.95
52 Week Low	US$13.72
Beta	1.29
1 Month Change	23.55%
3 Month Change	13.05%
1 Year Change	342.57%
3 Year Change	210.25%
5 Year Change	n/a
Change since IPO	61.18%

Recent updates

Shareholder Returns

	A2RR34	BR Biotechs	BR Market
7D	1.0%	0.8%	-3.3%
1Y	342.6%	17.5%	9.8%

Return vs Industry: A2RR34 exceeded the BR Biotechs industry which returned 19.6% over the past year.

Return vs Market: A2RR34 exceeded the BR Market which returned 9.9% over the past year.

Price Volatility

Is A2RR34's price volatile compared to industry and market?
A2RR34 volatility
A2RR34 Average Weekly Movement	10.0%
Biotechs Industry Average Movement	9.3%
Market Average Movement	4.2%
10% most volatile stocks in BR Market	8.4%
10% least volatile stocks in BR Market	1.8%

Stable Share Price: A2RR34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: A2RR34's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of BR stocks.

About the Company

Founded	Employees	CEO	Website
2003	711	Chris Anzalone	arrowheadpharma.com

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.

Arrowhead Pharmaceuticals, Inc. Fundamentals Summary

How do Arrowhead Pharmaceuticals's earnings and revenue compare to its market cap?
A2RR34 fundamental statistics
Market cap	R$63.90b
Earnings (TTM)	-R$1.67b
Revenue (TTM)	R$3.50b

18.3x

P/S Ratio

-38.3x

P/E Ratio

Is A2RR34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A2RR34 income statement (TTM)
Revenue	US$669.50m
Cost of Revenue	US$0
Gross Profit	US$669.50m
Other Expenses	US$989.45m
Earnings	-US$319.95m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-2.27
Gross Margin	100.00%
Net Profit Margin	-47.79%
Debt/Equity Ratio	270.3%

How did A2RR34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/15 01:16
End of Day Share Price	2026/08/14 00:00
Earnings	2026/06/30
Annual Earnings	2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arrowhead Pharmaceuticals, Inc. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ying Huang	Barclays
William Pickering	Bernstein
Jason Matthew Gerberry	BofA Global Research

Arrowhead Pharmaceuticals (A2RR34) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Arrowhead Pharmaceuticals, Inc. Competitors

Blau Farmacêutica

Biomm

Krystal Biotech

BridgeBio Pharma

Price History & Performance

Recent News & Updates

Arrowhead Pharmaceuticals Completes Enrollment In Global Phase 3 Yosemite Study Of Zodasiran For The Treatment Of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 And SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Index

Arrowhead Pharmaceuticals Receives Marketing Authorization In The European Union For REDEMPLO (Plozasiran) To Reduce Triglycerides In Adults With Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Announces Appointment of Dr. Matt Cohen as Director, Effective June 12, 2026

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Recent updates

Arrowhead Pharmaceuticals Completes Enrollment In Global Phase 3 Yosemite Study Of Zodasiran For The Treatment Of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 And SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Index

Arrowhead Pharmaceuticals Receives Marketing Authorization In The European Union For REDEMPLO (Plozasiran) To Reduce Triglycerides In Adults With Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Announces Appointment of Dr. Matt Cohen as Director, Effective June 12, 2026

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Pharmaceuticals Presents New Positive Clinical Data for Plozasiran at the 94th European Atherosclerosis Society Congress

Arrowhead Pharmaceuticals Inc Receives Tga Approval of Redemplo (Plozasiran) in Australia Expanding Global Access for Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval Of REDEMPLO (Plozasiran) To Reduce Triglycerides In Adults With Familial Chylomicronemia Syndrome In Europe

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy And Safety Data For Plozasiran Across A Spectrum Of Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 05, 2026

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 19, 2026

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.998502 million.

Arrowhead Pharmaceuticals Announces Nmpa Approval of Redemplo (Plozasiran) for Familial Chylomicronemia Syndrome in China

Arrowhead Pharmaceuticals Announces Health Canada Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Ionis Pharmaceuticals, Inc. Files Complaint for Patent Infringement Against Arrowhead Pharmaceuticals, Inc

Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Enrollment in Shasta-3, Shasta-4, and Muir-3 Phase 3 Studies of Plozasiran

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of Aro-Alk7 for the Treatment of Obesity

Arrowhead Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 13, 2025

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals, Inc. Presents Preclinical Data on Aro-Alk7 for Treatment of Obesity

Arrowhead Pharmaceuticals, Inc. Appoints Douglas Ingram as Director

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2025

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE